Incidence of Dyslipidemia Elevated During COVID-19 Pandemic
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 14, 2024 -- There was an increase in dyslipidemia incidence during the COVID-19 pandemic compared with the prepandemic period, according to a study published online Sept. 12 in the Journal of Clinical Investigation.
Valentina Trimarco, from Federico II University in Naples, Italy, and colleagues conducted a six-year longitudinal study to examine the broader effects of COVID-19 on the incidence of dyslipidemia in a real-world population of 228,266 individuals. Dyslipidemia incidence was compared during the COVID-19 pandemic (2020 to 2022) to the prepandemic period (2017 to 2019), with follow-up of at least 1,095 days (21,349,215 person-years).
The researchers found that the risk for developing dyslipidemia was increased during the COVID-19 period compared with the pre-COVID-19 period (odds ratio, 1.29), after adjustment for comorbidities in a multivariate analysis.
"The main finding of our study is the observation that the increased risk of dyslipidemia during the COVID-19 pandemic involved not only patients who had severe acute respiratory syndrome coronavirus 2 infection but the whole population," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-15 06:00
Read more
- 'Dawson's Creek' Star James Van Der Beek Has Colon Cancer
- Better Prepared Emergency Departments Could Save Children's Lives
- Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
- Complete Vaccination Coverage Down in Kindergarteners for 2023-24 School Year
- America's Epidemic of STDs May Finally Be Slowing
- Big Post-Election Surge Seen in Online Sales of Morning-After Pills
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions